These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 37112909)

  • 41. SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity.
    Jaycox JR; Lucas C; Yildirim I; Dai Y; Wang EY; Monteiro V; Lord S; Carlin J; Kita M; Buckner JH; Ma S; Campbell M; Ko A; Omer S; Lucas CL; Speake C; Iwasaki A; Ring AM
    Nat Commun; 2023 Mar; 14(1):1299. PubMed ID: 36894554
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lymphohistiocytic Myocarditis Possibly Due to Moderna mRNA-1273 Vaccine.
    Chow BT; Lai CK
    Am J Clin Pathol; 2022 Aug; 158(2):167-172. PubMed ID: 35285858
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review.
    Fiolet T; Kherabi Y; MacDonald CJ; Ghosn J; Peiffer-Smadja N
    Clin Microbiol Infect; 2022 Feb; 28(2):202-221. PubMed ID: 34715347
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Myocarditis and pericarditis in adolescents after first and second doses of mRNA COVID-19 vaccines.
    Foltran D; Delmas C; Flumian C; De Paoli P; Salvo F; Gautier S; Drici MD; Karsenty C; Montastruc F
    Eur Heart J Qual Care Clin Outcomes; 2022 Mar; 8(2):99-103. PubMed ID: 34849667
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical cardiovascular emergencies and the cellular basis of COVID-19 vaccination: from dream to reality?
    Li YE; Wang S; Reiter RJ; Ren J
    Int J Infect Dis; 2022 Nov; 124():1-10. PubMed ID: 36075372
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Acute myocarditis caused by COVID-19 disease and following COVID-19 vaccination.
    Kornowski R; Witberg G
    Open Heart; 2022 Mar; 9(1):. PubMed ID: 35264415
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Myocarditis after vaccination against covid-19.
    Gellad WF
    BMJ; 2021 Dec; 375():n3090. PubMed ID: 34916217
    [No Abstract]   [Full Text] [Related]  

  • 48. Anti-SARS-CoV-2 vaccine-induced myocarditis - real but, in general, rare and mild: A consensus statement from the Studies Committee of the Portuguese Society of Cardiology.
    Sousa JP; Roque D; Guerreiro C; Teixeira R;
    Rev Port Cardiol; 2023 Feb; 42(2):161-167. PubMed ID: 36621565
    [TBL] [Abstract][Full Text] [Related]  

  • 49. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Acute myocarditis after COVID-19 vaccination.
    Saadi SM; Bossei AA; Alsulimani LK
    Saudi Med J; 2022 Nov; 43(11):1270-1275. PubMed ID: 36379527
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vaccination-Associated Myocarditis and Myocardial Injury.
    Altman NL; Berning AA; Mann SC; Quaife RA; Gill EA; Auerbach SR; Campbell TB; Bristow MR
    Circ Res; 2023 May; 132(10):1338-1357. PubMed ID: 37167355
    [TBL] [Abstract][Full Text] [Related]  

  • 52. mRNA Vaccines against SARS-CoV-2: Advantages and Caveats.
    Echaide M; Chocarro de Erauso L; Bocanegra A; Blanco E; Kochan G; Escors D
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983017
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021.
    Gargano JW; Wallace M; Hadler SC; Langley G; Su JR; Oster ME; Broder KR; Gee J; Weintraub E; Shimabukuro T; Scobie HM; Moulia D; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2021 Jul; 70(27):977-982. PubMed ID: 34237049
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of SARS-CoV-2 mRNA-Vaccine on the Induction of Myocarditis in Different Murine Animal Models.
    Zirkenbach VA; Ignatz RM; Öttl R; Cehreli Z; Stroikova V; Kaya M; Lehmann LH; Preusch MR; Frey N; Kaya Z
    Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902442
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.
    Mallory RM; Formica N; Pfeiffer S; Wilkinson B; Marcheschi A; Albert G; McFall H; Robinson M; Plested JS; Zhu M; Cloney-Clark S; Zhou B; Chau G; Robertson A; Maciejewski S; Hammond HL; Baracco L; Logue J; Frieman MB; Smith G; Patel N; Glenn GM;
    Lancet Infect Dis; 2022 Nov; 22(11):1565-1576. PubMed ID: 35963274
    [TBL] [Abstract][Full Text] [Related]  

  • 56. COVID-19, Myocarditis and Pericarditis.
    Fairweather D; Beetler DJ; Di Florio DN; Musigk N; Heidecker B; Cooper LT
    Circ Res; 2023 May; 132(10):1302-1319. PubMed ID: 37167363
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Humoral and Cellular Immune Responses to Vector, Mix-and-Match, or mRNA Vaccines against SARS-CoV-2 and the Relationship between the Two Immune Responses.
    Nam M; Yun SG; Kim SW; Kim CG; Cha JH; Lee C; Kang S; Park SG; Kim SB; Lee KB; Chung YS; Nam MH; Lee CK; Cho Y
    Microbiol Spectr; 2022 Aug; 10(4):e0249521. PubMed ID: 35946811
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects.
    Wheeler SE; Shurin GV; Yost M; Anderson A; Pinto L; Wells A; Shurin MR
    Microbiol Spectr; 2021 Sep; 9(1):e0034121. PubMed ID: 34346750
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Myocarditis Following Coronavirus Disease 2019 mRNA Vaccine: A Case Series and Incidence Rate Determination.
    Perez Y; Levy ER; Joshi AY; Virk A; Rodriguez-Porcel M; Johnson M; Roellinger D; Vanichkachorn G; Charles Huskins W; Swift MD
    Clin Infect Dis; 2022 Aug; 75(1):e749-e754. PubMed ID: 34734240
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2.
    Salleh MZ; Norazmi MN; Deris ZZ
    PeerJ; 2022; 10():e13083. PubMed ID: 35287350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.